Idiopathic pulmonary fibrosis: An Australian perspective

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis is a progressive interstitial lung disease of unknown aetiology with a dismal median survival of 3 years. Patients typically develop progressive dyspnoea and increasing exercise limitation. With a rising incidence and prevalence, an unpredictable disease course and limited treatment options, it is rapidly becoming an important public health concern. To date, lung transplantation has been the sole viable hope for treatment for those who qualify. However, the landscape of idiopathic pulmonary fibrosis management is changing, with the recent emergence of novel pharmacotherapy shown to have a favourable influence on the natural history of this disease.
Original languageEnglish
Pages (from-to)663-668
Number of pages6
JournalInternal Medicine Journal
Volume46
Issue number6
DOIs
Publication statusPublished - 1 Jun 2016

Keywords

  • IPF exacerbation
  • IPF MDM
  • IPF review
  • IPF transplant
  • IPF treatment
  • Idiopathic pulmonary fibrosis

Cite this